{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:03:07Z","timestamp":1793638987411,"version":"4.5.1"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Serum albumin (SA), the most abundant soluble protein in the body, maintains plasma oncotic pressure and regulates the distribution of vascular fluid and has a range of other important functions. The goals of this review are to expand clinical knowledge regarding the functions of SA, elucidate effects of dysregulated SA concentration, and discuss the clinical relevance of hypoalbuminemia resulting from various diseases. We discuss potential repercussions of SA dysregulation on cholesterol levels, liver function, and other processes that rely on its homeostasis, as decreased SA concentration has been shown to be associated with increased risk for cardiovascular disease, hyperlipidemia, and mortality. We describe the anti-inflammatory and antioxidant properties of SA, as well as its ability to bind and transport a plethora of endogenous and exogenous molecules. SA is the primary serum protein involved in binding and transport of drugs and as such has the potential to affect, or be affected by, certain medications. Of current relevance are antibody-based inhibitors of the neonatal Fc receptor (FcRn), several of which are under clinical development to treat immunoglobulin G (IgG)-mediated autoimmune disorders; some have been shown to decrease SA concentration. FcRn acts as a homeostatic regulator of SA by rescuing it, as well as IgG, from intracellular degradation\n                    <jats:italic>via<\/jats:italic>\n                    a common cellular recycling mechanism. Greater clinical understanding of the multifunctional nature of SA and the potential clinical impact of decreased SA are needed; in particular, the potential for certain treatments to reduce SA concentration, which may affect efficacy and toxicity of medications and disease progression.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.892534","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:32:12Z","timestamp":1654083132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":120,"title":["Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders"],"prefix":"10.3389","volume":"13","author":[{"given":"E. Sally","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Van Santbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Terje","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"Sleep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Louagie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gestur","family":"Vidarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2036.16.s5.2.x","article-title":"Review Article: Albumin as a Drug\u2013Biological Effects of Albumin Unrelated to Oncotic Pressure","author":"Evans","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00299","article-title":"Unraveling the Mysteries of Serum Albumin-More Than Just a Serum Protein","volume":"5","author":"Merlot","year":"2014","journal-title":"Front Physiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2010.12.003","article-title":"The Glycation of Albumin: Structural and Functional Impacts","volume":"93","author":"Rondeau","year":"2011","journal-title":"Biochimie"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2019.1693056","article-title":"Impaired Albumin Function: A Novel Potential Indicator for Liver Function Damage","volume":"51","author":"Sun","year":"2019","journal-title":"Ann Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/nu9080829","article-title":"Evaluation of Blood Biomarkers Associated With Risk of Malnutrition in Older Ddults: A Systematic Review and Meta-Analysis","volume":"9","author":"Zhang","year":"2017","journal-title":"Nutrients"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190320105316","article-title":"Structural Basis of Drug Recognition by Human Serum Albumin","volume":"27","author":"Leboffe","year":"2020","journal-title":"Curr Med Chem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2013.05.005","article-title":"Albumin-Drug Interaction and its Clinical Implication","volume":"1830","author":"Yamasaki","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1451","article-title":"Hypoalbuminemia: Pathogenesis and Clinical Significance","volume":"43","author":"Soeters","year":"2019","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0012.0916","article-title":"New Insights About Albumin and Liver Disease","volume":"17","author":"Carvalho","year":"2018","journal-title":"Ann Hepatol"},{"key":"B10","article-title":"Fluid and Electrolyte Therapy","volume-title":"The Veterinary ICU Book","author":"Wingfield","year":"2002"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S102819","article-title":"Human Serum Albumin Homeostasis: A New Look at the Roles of Synthesis, Catabolism, Renal and Gastrointestinal Excretion, and the Clinical Value of Serum Albumin Measurements","volume":"9","author":"Levitt","year":"2016","journal-title":"Int J Gen Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2000.278.2.E352","article-title":"Measurement of Interstitial Albumin in Human Skeletal Muscle and Adipose Tissue by Open-Flow Microperfusion","volume":"278","author":"Ellmerer","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.300","article-title":"Albumin as Fatty Acid Transporter","volume":"24","author":"van der Vusse","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of Lipid Metabolism in Nephrotic Syndrome: Mechanisms and Consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2018.09.007","article-title":"Crosstalk Between Zinc and Free Fatty Acids in Plasma","volume":"1864","author":"Coverdale","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2013.04.012","article-title":"Novel Insights Into the Pleiotropic Effects of Human Serum Albumin in Health and Disease","volume":"1830","author":"Ha","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/15216540500404093","article-title":"The Extraordinary Ligand Binding Properties of Human Serum Albumin","volume":"57","author":"Fasano","year":"2005","journal-title":"IUBMB Life"},{"key":"B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-017-0111-x","article-title":"Critical Appraisal of the Role of Serum Albumin in Cardiovascular Disease","volume":"5","author":"Chien","year":"2017","journal-title":"Biomark Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2174\/092986608784246542","article-title":"The Interaction Between Cholesterol and Human Serum Albumin","volume":"15","author":"Peng","year":"2008","journal-title":"Protein Pept Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15033580","article-title":"Interactive Association of Drugs Binding to Human Serum Albumin","volume":"15","author":"Yang","year":"2014","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/2110-5820-3-4","article-title":"Specific Antioxidant Properties of Human Serum Albumin","volume":"3","author":"Taverna","year":"2013","journal-title":"Ann Intensive Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2008.04.057","article-title":"The Antioxidant Properties of Serum Albumin","volume":"582","author":"Roche","year":"2008","journal-title":"FEBS Lett"},{"key":"B23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jhep.2014.04.012","article-title":"Human Serum Albumin, Systemic Inflammation, and Cirrhosis","volume":"61","author":"Arroyo","year":"2014","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/bja\/85.4.599","article-title":"The Role of Albumin in Critical Illness","volume":"85","author":"Nicholson","year":"2000","journal-title":"Br J Anaesth"},{"key":"B25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s0065-2776(09)03004-1","article-title":"Chapter 4 Multitasking by Exploitation of Intracellular Transport Functions","volume":"103","author":"Ward","year":"2009","journal-title":"Adv Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.522565","article-title":"Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-Blocking Antibodies","volume":"289","author":"Sand","year":"2014","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021829","article-title":"The Major Histocompatibility Complex-Related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs its Lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636556","article-title":"The Conserved Histidine 166 Residue of the Human Neonatal Fc Receptor Heavy Chain is Critical for the pH-Dependent Binding to Albumin","volume":"36","author":"Andersen","year":"2006","journal-title":"Eur J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.537563","article-title":"Structural Insights Into Neonatal Fc Receptor-Based Recycling Mechanisms","volume":"289","author":"Oganesyan","year":"2014","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.07.023","article-title":"Cellular Recycling-Driven In Vivo Half-Life Extension Using Recombinant Albumin Fusions Tuned for Neonatal Fc Receptor (FcRn) Engagement","volume":"287","author":"Larsen","year":"2018","journal-title":"J Control Release"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2013.08.022","article-title":"Crystal Structure of an HSA\/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface","volume":"21","author":"Schmidt","year":"2013","journal-title":"Structure"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00682","article-title":"Unraveling the Interaction Between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics","volume":"5","author":"Sand","year":"2014","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2021","article-title":"Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn","volume":"172","author":"Ober","year":"2004","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1618291114","article-title":"Hepatic FcRn Regulates Albumin Homeostasis and Susceptibility to Liver Injury","volume":"114","author":"Pyzik","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1602459","article-title":"Neonatal Fc Receptor Expression in Macrophages is Indispensable for IgG Homeostasis","volume":"11","author":"Challa","year":"2019","journal-title":"MAbs"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540","article-title":"The Neonatal Fc Receptor (FcRn): A Misnomer","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/bi052628y","article-title":"Albumin Binding to FcRn: Distinct From the FcRn-IgG Interaction","volume":"45","author":"Chaudhury","year":"2006","journal-title":"Biochemistry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1490119","article-title":"Extending Human IgG Half-Life Using Structure-Guided Design","volume":"10","author":"Booth","year":"2018","journal-title":"MAbs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.24981","article-title":"Analytical FcRn Affinity Chromatography for Functional Characterization of Monoclonal Antibodies","volume":"5","author":"Schlothauer","year":"2013","journal-title":"MAbs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1073\/pnas.1408766112","article-title":"Charge-Mediated Influence of the Antibody Variable Domain on FcRn-Dependent Pharmacokinetics","volume":"112","author":"Schoch","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1038\/s41598-019-40731-2","article-title":"Reduced FcRn-Mediated Transcytosis of IgG2 Due to a Missing Glycine in its Lower Hinge","volume":"9","author":"Stapleton","year":"2019","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810796106","article-title":"Conditional Deletion of the MHC Class I-Related Receptor FcRn Reveals the Sites of IgG Homeostasis in Mice","volume":"106","author":"Montoyo","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0580","article-title":"An Engineered Human Albumin Enhances Half-Life and Transmucosal Delivery When Fused to Protein-Based Biologics","volume":"12","author":"Bern","year":"2020","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00286.2005","article-title":"Albumin Turnover: FcRn-Mediated Recycling Saves as Much Albumin From Degradation as the Liver Produces","volume":"290","author":"Kim","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013090950","article-title":"The Proximal Tubule and Albuminuria: Really","volume":"25","author":"Dickson","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013010018","article-title":"Albumin is Recycled From the Primary Urine by Tubular Transcytosis","volume":"24","author":"Tenten","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008090976","article-title":"Renal FcRn Reclaims Albumin But Facilitates Elimination of IgG","volume":"20","author":"Sarav","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1982.tb02671.x","article-title":"Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations","volume":"22","author":"Greenblatt","year":"1982","journal-title":"J Clin Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707251","article-title":"Physiological and Pathological Changes in the Redox State of Human Serum Albumin Critically Influence its Binding Properties","volume":"151","author":"Oettl","year":"2007","journal-title":"Br J Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/molecules25030618","article-title":"Human Serum Albumin Aggregation\/Fibrillation and its Abilities to Drugs Binding","volume":"25","author":"Maciazek-Jurczyk","year":"2020","journal-title":"Molecules"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2013.04.023","article-title":"Albumin as a Versatile Platform for Drug Half-Life Extension","volume":"1830","author":"Sleep","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing Albumin as a Carrier for Cancer Therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-10-20","article-title":"Effect of Blood Protein Concentrations on Drug-Dosing Regimes: Practical Guidance","volume":"10","author":"Gurevich","year":"2013","journal-title":"Theor Biol Med Model"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.03.002","article-title":"Clinical Implications Associated With the Posttranslational Modification-Induced Functional Impairment of Albumin in Oxidative Stress-Related Diseases","volume":"106","author":"Watanabe","year":"2017","journal-title":"J Pharm Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cca.2013.07.013","article-title":"Review: Glycation of Human Serum Albumin","volume":"425","author":"Anguizola","year":"2013","journal-title":"Clin Chim Acta"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3733","article-title":"Human Serum Albumin Presents Isoform Variants With Altered Neonatal Fc Receptor Interactions","volume":"28","author":"Leblanc","year":"2019","journal-title":"Protein Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2019.06.023","article-title":"Pro-Oxidant and Pro-Inflammatory Effects of Glycated Albumin on Cardiomyocytes","volume":"144","author":"Martinez Fernandez","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/antiox9080763","article-title":"S-Thiolation Targets Albumin in Heart Failure","volume":"9","author":"Brioschi","year":"2020","journal-title":"Antioxid (Basel)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-002-0328-8","article-title":"Binding of Pyridostigmine Bromide, N,N-Diethyl-M-Toluamide and Permethrin, Alone and in Combinations, to Human Serum Albumin","volume":"76","author":"Abu-Qare","year":"2002","journal-title":"Arch Toxicol"},{"key":"B61","unstructured":"2017"},{"key":"B62","unstructured":"FY2015 Regulatory Science Research Report: Narrow Therapeutic Index Drugs2017"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9562.1000317","article-title":"Myasthenia Gravis and its Comorbidities","volume":"6","author":"Cacho Diaz","year":"2015","journal-title":"J Neurol Neurophysiol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2217\/clp.13.5","article-title":"Increased Frequency of Microalbuminuria in Patients Receiving Statins","volume":"8","author":"Robles","year":"2013","journal-title":"Clin Lipidol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-s249","article-title":"Microalbuminuria in Type 2 Diabetes and Hypertension: A Marker, Treatment Target, or Innocent Bystander","author":"Basi","year":"2008","journal-title":"Diabetes Care"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21074","article-title":"Statins may Aggravate Myasthenia Gravis","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp065","article-title":"Dyslipidemia and Cardiovascular Risk: The Importance of Early Prevention","volume":"102","author":"Miller","year":"2009","journal-title":"QJM"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081208","article-title":"The Effect of Plasma Protein Binding on the Therapeutic Monitoring of Antiseizure Medications","volume":"13","author":"Charlier","year":"2021","journal-title":"Pharmaceutics"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02092-w","article-title":"Albumin and Bleed Risk in Rivaroxaban Treated Patients","volume":"50","author":"Wojakowski","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(01)00957-3","article-title":"Hypoalbuminemia as a Risk Factor for Over-Anticoagulation","volume":"112","author":"Tincani","year":"2002","journal-title":"Am J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.07.020","article-title":"Low Albumin Levels are Associated With Mortality Risk in Hospitalized Patients","volume":"130","author":"Akirov","year":"2017","journal-title":"Am J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005000","article-title":"Low Serum Albumin Concentrations are Associated With Disease Severity in Patients With Myasthenia Gravis","volume":"95","author":"Weng","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ancard.2020.07.012","article-title":"Serum Albumin and Cardiovascular Disease: State-Of-the-Art Review","volume":"69","author":"Arques","year":"2020","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014030267","article-title":"Nephrotic Syndrome: Components, Connections, and Angiopoietin-Like 4-Related Therapeutics","volume":"25","author":"Mace","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005121288","article-title":"Microalbuminuria and Risk for Cardiovascular Disease: Analysis of Potential Mechanisms","volume":"17","author":"Stehouwer","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/srep03884","article-title":"The Prevalence, Characteristics, and Clinical Significance of Abnormal Albuminuria in Patients With Hypertension","volume":"4","author":"Murai","year":"2014","journal-title":"Sci Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1008345","article-title":"Albumin-Deficient Mouse Models for Studying Metabolism of Human Albumin and Pharmacokinetics of Albumin-Based Drugs","volume":"7","author":"Roopenian","year":"2015","journal-title":"MAbs"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00204.x","article-title":"A Simultaneous Study of the Metabolism of Apolipoprotein B and Albumin in Nephrotic Patients","volume":"54","author":"Demant","year":"1998","journal-title":"Kidney Int"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-004-1492-z","article-title":"Congenital Analbuminaemia: Biochemical and Clinical Implications. A Case Report and Literature Review","volume":"163","author":"Koot","year":"2004","journal-title":"Eur J Pediatr"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M031336","article-title":"Serum Albumin Acts as a Shuttle to Enhance Cholesterol Efflux From Cells","volume":"54","author":"Sankaranarayanan","year":"2013","journal-title":"J Lipid Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318843","article-title":"Albumin in Decompensated Cirrhosis: New Concepts and Perspectives","volume":"69","author":"Bernardi","year":"2020","journal-title":"Gut"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000031732.78052.81","article-title":"Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13289","article-title":"Antioxidant Status of Serum Bilirubin, Uric Acid and Albumin in Pemphigus Vulgaris","volume":"43","author":"Li","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4480","article-title":"Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barre Syndrome","volume":"74","author":"Fokkink","year":"2017","journal-title":"JAMA Neurol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2015.1134526","article-title":"Low Antioxidant Status of Serum Bilirubin, Uric Acid, Albumin and Creatinine in Patients With Myasthenia Gravis","volume":"126","author":"Yang","year":"2016","journal-title":"Int J Neurosci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27247","article-title":"Assessment of Clinical Factors Affecting Outcome of Myasthenia Gravis","volume":"64","author":"Yoshimoto","year":"2021","journal-title":"Muscle Nerve"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115755","article-title":"Fc-Receptor Targeted Therapies for the Treatment of Myasthenia Gravis","volume":"22","author":"Keller","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG Regulation Through FcRn Blocking: A Novel Mechanism for the Treatment of Myasthenia Gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J Neurol Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1505464","article-title":"Generation and Characterization of a High Affinity Anti-Human FcRn Antibody, Rozanolixizumab, and the Effects of Different Molecular Formats on the Reduction of Plasma IgG Concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn Inhibitor Rozanolixizumab Reduces Human Serum IgG Concentration: A Randomized Phase 1 Study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V126.23.3472.3472","article-title":"M281: A Therapeutic FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and Other Autoimmune Diseases","volume":"126","author":"Ling","year":"2015","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in Humans Reduces Circulating IgG Levels and Inhibits IgG Immune Complex-Mediated Immune Responses","volume":"12","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13019","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HBM9161, a Novel FcRn Inhibitor, in a Phase I Study for Healthy Chinese Volunteers","volume":"14","author":"Yap","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B96","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079","article-title":"RVT-1401, a Novel Anti-FcRn Monoclonal Antibody, is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration P5.2\u2013079","volume":"92","author":"Collins","year":"2019","journal-title":"Neurology"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc Receptor Antagonist Efgartigimod Safely and Sustainably Reduces IgGs in Humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 Multiple-Dose Study of an FcRn Inhibitor, Rozanolixizumab, in Patients With Primary Immune Thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","article-title":"Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus","volume":"141","author":"Werth","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027760","article-title":"Updates on the Understanding and Management of Thyroid Eye Disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients With Primary Immune Thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782","article-title":"Treatment of Pemphigus Vulgaris and Foliaceus With Efgartigimod, a Neonatal Fc Receptor Inhibitor: A Phase II Multicentre, Open-Label Feasibility Trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, Efficacy, and Tolerability of Efgartigimod in Patients With Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B105","unstructured":"Vyvgart ArgenxPrescribing Information2021"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc Region of Immunoglobulin G to Modulate In Vivo Antibody Levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E13-04-0174","article-title":"Multivalent Immune Complexes Divert FcRn to Lysosomes by Exclusion From Recycling Sorting Tubules","volume":"24","author":"Weflen","year":"2013","journal-title":"Mol Biol Cell"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116428","article-title":"Myasthenia Gravis: Historical Achievements and the \"Golden Age\" of Clinical Trials","volume":"406","author":"Nguyen-Cao","year":"2019","journal-title":"J Neurol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.892534\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T03:31:57Z","timestamp":1727321517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.892534\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":108,"alternative-id":["10.3389\/fimmu.2022.892534"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.892534","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"892534"}}